To validate whether Vpr induces LAPTM5 degradation, we infected MDMs with wild-type or Vpr-defective HIV-1AD8 in the presence or absence of Efavirenz (EFV) or raltegravir, which block HIV-1 productive infection. Here, LAPTM5 is linked to infection.